Immunohistochemical expression of HIK1083 and MUC6 in endometrial carcinomas

Histopathology. 2019 Oct;75(4):552-558. doi: 10.1111/his.13887. Epub 2019 Aug 8.

Abstract

Aims: Gastric-type endocervical adenocarcinoma (EA) is characterised by aggressive behaviour and pathogenesis independent of human papillomavirus infection. Because of its morphology and frequent mutation-pattern expression of p53, gastric-type EA may be confused with several types of endometrial carcinoma, particularly in biopsy and curettage specimens. HIK1083 and MUC6 are immunohistochemical markers used to support a diagnosis of gastric-type EA; however, the rates of expression of these markers in endometrial tumours are largely unknown. We therefore aimed to assess the expression of HIK1083 and MUC6 in a cohort of different types of endometrial carcinoma.

Methods and results: Ninety-one endometrial carcinomas (56 endometrioid, 16 clear cell, and 19 serous) from 91 patients treated with hysterectomy were included. A representative tumour block from each case was used for immunohistochemical staining with HIK1083 and MUC6. The percentage of stained cells (0-100%) and average staining intensity (weak, moderate, and strong) were recorded for both markers. None of 91 cases expressed HIK1083. In contrast, 66% (60/91) of cases showed at least focal expression of MUC6; importantly, 54 of 60 (90%) positive cases showed moderate or strong staining. Five of 60 (8%) cases showed MUC6 staining in ≥50% of tumour cells. Endometrioid tumours (49/56, 88%) were more likely to express MUC6 than cases of clear cell (1/16, 6%) or serous (10/19, 53%) carcinoma.

Discussion: Endometrial carcinoma often expresses MUC6. In contrast, HIK1083 is consistently negative, and thus, when positive, is a more reliable marker for distinguishing gastric-type EA from some of its endometrial mimics.

Keywords: HIK1083; MUC6; endometrial carcinoma; gastric-type adenocarcinoma.

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Biomarkers, Tumor / analysis*
  • Endometrial Neoplasms / diagnosis*
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Mucin-6 / analysis
  • Mucin-6 / biosynthesis*

Substances

  • Biomarkers, Tumor
  • MUC6 protein, human
  • Mucin-6